A New England-based nonprofit is targeting a philanthropic fund that specifically supports scientific discoveries targeting oncology that show significant clinical potential, but which remain stuck due to insufficient funding. The organization’s primary mandate is to increase the number of cancer treatment discoveries that undergo early stage product development so that more successful treatments will make it through the pipeline.
The organization intends to write grants to emerging biotechs developing preclinical technologies. Average allocations are expected to be in the hundreds of thousands, and will be made on an opportunistic basis. Though the organization will look at opportunities across the scope of oncology therapeutics and diagnostics, companies developing molecular technologies are of particular interest.
Next Phase Newsletter 
Leave a comment